Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04916002
Title CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Checkmate Pharmaceuticals
Indications

triple-receptor negative breast cancer

skin squamous cell carcinoma

Merkel cell carcinoma

Therapies

Cemiplimab + QbG10

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.